The Prevalence and Molecular Epidemiology of Hepatitis Delta Virus in Nigeria: The Results of a Nationwide Study
Ijeoma Maryjoy Ifeorah(University of Nigeria), Emmanuel Gordien(Inserm), Chakib Alloui(Université Paris Cité), Ségolène Brichler(Inserm), Moses Olubusuyi Adewumi(University of Ibadan), Samira Dziri(Université Paris Cité), Athénaïs Gerber(Université Paris Cité), Gatuwa Aglavdawa(Gombe State University), Peyou-Amed B. Ghapouen(Taraba State University), Frédéric Le Gal(Sorbonne Université), Solomon A. Bakarey(University of Ibadan), Stephen Okoroafor Kalu(Nnamdi Azikiwe University Teaching Hospital)
Cited by 6
Related Papers
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
|The Lancet. Gastroenterology & hepatology|2017|249
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up
|Hepatology|2006|238
Molecular Phylogenetic Analyses Indicate a Wide and Ancient Radiation of African Hepatitis Delta Virus, Suggesting a <i>Deltavirus</i> Genus of at Least Seven Major Clades
|Journal of Virology|2004|221
Eighth Major Clade for Hepatitis Delta Virus
|Emerging infectious diseases|2006|206
Inhibition of Hepatitis B Virus Replication by the Interferon-Inducible MxA Protein
|Journal of Virology|2001|185